PURPOSE: Colorectal cancer predominantly occurs in the elderly, but approximately 5% of patients are 50 years old or younger. We sought to determine whether young age is prognostic, or whether it influences efficacy/toxicity of chemotherapy, in patients with advanced disease. METHODS: We analyzed individual data on 6,284 patients from nine phase III trials of advanced colorectal cancer (aCRC) that used fluorouracil-based single-agent and combination chemotherapy. End points included progression-free survival (PFS), overall survival (OS), response rate (RR), and grade 3 or worse adverse events. Stratified Cox and adjusted logistic-regression models were used to test for age effects and age-treatment interactions. RESULTS: A total of 793 patients (13%) were younger than 50 years old; 188 of these patients (3% of total patients) were younger than 40 years old. Grade 3 or worse nausea (10% v 7%; P = .01) was more common, and severe diarrhea (11% v 14%; P = .001) and neutropenia (23% v 26%; P < .001) were less common in young (younger than 50 years) than in older (older than 50 years) patients. Age was prognostic for PFS, with poorer outcomes occurring in those younger than 50 years (median, 6.0 v 7.5 months; hazard ratio, 1.10; P = .02), but it did not affect RR or OS. In the subset of monotherapy versus combination chemotherapy trials, the relative benefits of multiagent chemotherapy were similar for young and older patients. Results were comparable when utilizing an age cut point of 40 years. CONCLUSION: Young age is modestly associated with poorer PFS but not OS or RR in treated patients with aCRC, and young patients have more nausea but less diarrhea and neutropenia with chemotherapy in general. Young versus older patients derive the same benefits from combination chemotherapy. Absent results of a clinical trial, standard combination chemotherapy approaches are appropriate for young patients with aCRC.
PURPOSE:Colorectal cancer predominantly occurs in the elderly, but approximately 5% of patients are 50 years old or younger. We sought to determine whether young age is prognostic, or whether it influences efficacy/toxicity of chemotherapy, in patients with advanced disease. METHODS: We analyzed individual data on 6,284 patients from nine phase III trials of advanced colorectal cancer (aCRC) that used fluorouracil-based single-agent and combination chemotherapy. End points included progression-free survival (PFS), overall survival (OS), response rate (RR), and grade 3 or worse adverse events. Stratified Cox and adjusted logistic-regression models were used to test for age effects and age-treatment interactions. RESULTS: A total of 793 patients (13%) were younger than 50 years old; 188 of these patients (3% of total patients) were younger than 40 years old. Grade 3 or worse nausea (10% v 7%; P = .01) was more common, and severe diarrhea (11% v 14%; P = .001) and neutropenia (23% v 26%; P < .001) were less common in young (younger than 50 years) than in older (older than 50 years) patients. Age was prognostic for PFS, with poorer outcomes occurring in those younger than 50 years (median, 6.0 v 7.5 months; hazard ratio, 1.10; P = .02), but it did not affect RR or OS. In the subset of monotherapy versus combination chemotherapy trials, the relative benefits of multiagent chemotherapy were similar for young and older patients. Results were comparable when utilizing an age cut point of 40 years. CONCLUSION: Young age is modestly associated with poorer PFS but not OS or RR in treated patients with aCRC, and young patients have more nausea but less diarrhea and neutropenia with chemotherapy in general. Young versus older patients derive the same benefits from combination chemotherapy. Absent results of a clinical trial, standard combination chemotherapy approaches are appropriate for young patients with aCRC.
Authors: C-H Köhne; E van Cutsem; J Wils; C Bokemeyer; M El-Serafi; M P Lutz; M Lorenz; P Reichardt; H Rückle-Lanz; N Frickhofen; R Fuchs; H-G Mergenthaler; T Langenbuch; U Vanhoefer; P Rougier; R Voigtmann; L Müller; B Genicot; O Anak; B Nordlinger Journal: J Clin Oncol Date: 2005-06-06 Impact factor: 44.544
Authors: Jessica B O'Connell; Melinda A Maggard; Jerome H Liu; David A Etzioni; Edward H Livingston; Clifford Y Ko Journal: World J Surg Date: 2004-06 Impact factor: 3.352
Authors: Rainer Porschen; Hendrik-Tobias Arkenau; Stephan Kubicka; Richard Greil; Thomas Seufferlein; Werner Freier; Albrecht Kretzschmar; Ullrich Graeven; Axel Grothey; Axel Hinke; Wolff Schmiegel; Hans-Joachim Schmoll Journal: J Clin Oncol Date: 2007-06-04 Impact factor: 44.544
Authors: Matthew T Seymour; Timothy S Maughan; Jonathan A Ledermann; Clare Topham; Roger James; Stephen J Gwyther; David B Smith; Stephen Shepherd; Anthony Maraveyas; David R Ferry; Angela M Meade; Lindsay Thompson; Gareth O Griffiths; Mahesh Kb Parmar; Richard J Stephens Journal: Lancet Date: 2007-07-14 Impact factor: 79.321
Authors: Fa Chen; Fei Wang; Christina E Bailey; Harvey J Murff; Jordan D Berlin; Xiao-Ou Shu; Wei Zheng Journal: Am J Cancer Res Date: 2020-10-01 Impact factor: 6.166
Authors: Stacy D Sanford; Fengmin Zhao; John M Salsman; Victor T Chang; Lynne I Wagner; Michael J Fisch Journal: Cancer Date: 2014-05-28 Impact factor: 6.860
Authors: Christopher H Bailey; Gayle Jameson; Chao Sima; Sharon Fleck; Erica White; Daniel D Von Hoff; Glen J Weiss Journal: J Cancer Date: 2011-11-28 Impact factor: 4.207
Authors: Christopher H Lieu; Lindsay A Renfro; Aimery de Gramont; Jeffrey P Meyers; Timothy S Maughan; Matthew T Seymour; Leonard Saltz; Richard M Goldberg; Daniel J Sargent; S Gail Eckhardt; Cathy Eng Journal: J Clin Oncol Date: 2014-09-20 Impact factor: 44.544
Authors: En Cheng; Holly N Blackburn; Kimmie Ng; Donna Spiegelman; Melinda L Irwin; Xiaomei Ma; Cary P Gross; Fred K Tabung; Edward L Giovannucci; Pamela L Kunz; Xavier Llor; Kevin Billingsley; Jeffrey A Meyerhardt; Nita Ahuja; Charles S Fuchs Journal: JAMA Netw Open Date: 2021-06-01